DEF 14A: Kairos Pharma Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals

Kairos Pharma announces its 2025 Annual Meeting of Stockholders to be held virtually on June 10, 2025, featuring proposals for director elections, auditor ratification, and executive compensation advisory votes.

Summary

• Kairos Pharma, Ltd. will hold its 2025 Annual Meeting of Stockholders on June 10, 2025, at 12 p.m. PT / 3 p.m. ET, conducted exclusively via live audio webcast and online stockholder tools.
• Stockholders of record as of April 29, 2025, are entitled to notice and to vote at the meeting.
• The meeting will address the election of four directors, ratification of Weinberg & Company, P.A. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, advisory votes on executive compensation, and the frequency of such advisory votes.
• The Board recommends voting FOR the election of each director nominee, FOR the ratification of the auditor appointment, FOR the advisory vote on executive compensation, and EVERY YEAR for the frequency of advisory votes on executive compensation.
• The proxy statement and the Annual Report are available at kairospharma.com.
• Stockholders can vote online at www.proxyvote.com, by telephone at 1-800-690-6903, or by mail.
• On the Record Date, there were 17,077,765 shares of Common Stock outstanding.

Sentiment

Score: 7

Explanation: The document is primarily informational and procedural, with a neutral tone. The Board's recommendations suggest a positive outlook on the company's direction, but there are also some negative points such as loans from officers and late filings.

Positives

• The virtual format of the Annual Meeting provides expanded access to stockholders regardless of location.
• Stockholders have multiple options for voting: online, by telephone, or by mail.
• The Board has established an audit committee, a compensation committee, and a nominating and corporate governance committee, each of which is made up of independent directors.
• The company has adopted a written Code of Business Conduct and Ethics that applies to all employees, officers, and directors.
• The company has adopted an insider trading policy which prohibits our directors, officers and employees from engaging in transactions in our common stock while in the possession of material non-public information.

Negatives

• The company borrowed $0.04 million from one of its officers in August 2024, accruing interest at 7.5% per annum.
• In April and May 2024, the Company borrowed $0.1 million from three of its officers, accruing interest at 7.5% per annum.
• Doug Samuelson filed a Form 4 late on 11/25/2024 for a transaction on 11/22/2024.
• Rahul Singhvi filed a Form 3 late on 04/30/2025 for a transaction on 12/10/2024.

Risks

• Failure to secure stockholder approval for key proposals could lead to changes in the company's governance and operations.
• The company's reliance on loans from officers, while converted to equity, indicates potential short-term funding challenges.
• Delinquent Section 16(a) reports indicate potential weaknesses in compliance procedures.
• The company is dependent on key personnel, and the loss of any of these individuals could adversely affect the company's operations.

Future Outlook

The document outlines the company's plans to hold its 2025 Annual Meeting and seek stockholder approval on key governance and operational matters. The Board's recommendations provide insight into the company's strategic direction.

Management Comments

• Dr. Yu is committed to advancing Kaiross pipeline to tackle the most unmet needs in cancer: resistance to cancer therapeutics and the suppressed immune response in cancer.
• The Audit Committee believes that the retention of Weinberg as our independent registered public accounting firm for fiscal year ending December 31, 2025 is in the best interests of our Company and our stockholders.

Industry Context

The proposals outlined in the proxy statement are standard for publicly traded companies and reflect typical corporate governance practices. The focus on executive compensation and auditor ratification aligns with regulatory requirements and investor expectations.

Comparison to Industry Standards

• The director compensation structure, including cash retainers and equity grants, is generally in line with industry practices for companies of similar size and stage.
• The virtual-only format for the annual meeting has become increasingly common, particularly among smaller companies, to enhance accessibility and reduce costs.
• The selection of Weinberg & Company, P.A. as the independent auditor is a critical decision, and the Audit Committee's rationale for the change is important for investor confidence.
• The company's executive compensation program, including base salaries and equity incentives, is designed to attract and retain talent in the competitive biotech industry.

Related Party Transactions

• In August 2024, the Company borrowed $0.04 million from one of its officers.
• In April and May 2024, the Company borrowed $0.1 million from three of its officers.
• The officers holding notes payable have since agreed to convert the outstanding loans and principal into shares of common stock of the company, converting at the IPO per share purchase price, following completion of the IPO.

Stakeholder Impact

• Stockholders will have the opportunity to vote on key proposals that will shape the company's governance and operations.
• Executive officers' compensation is subject to advisory votes, reflecting the importance of aligning management's interests with those of stockholders.
• The selection of the independent auditor is a critical decision that affects the reliability of the company's financial reporting.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold its Annual Meeting on June 10, 2025, to address the proposals.
• The Board will consider the voting results when making future decisions regarding executive compensation and other matters.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Board of Directors, Executive Compensation, Director Election, Auditor Ratification, Kairos Pharma